Cargando…

Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial

BACKGROUND: Upper respiratory tract infection symptoms are a common cause of morbidity. Herbal preparations of the plant Echinacea purpurea have immune-enhancing properties. OBJECTIVE: To compare the frequency of upper respiratory tract symptoms in individuals receiving E purpurea capsules and those...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neil, Joelle, Hughes, Susan, Lourie, Andrea, Zweifler, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129680/
https://www.ncbi.nlm.nih.gov/pubmed/18450126
http://dx.doi.org/10.1016/S1081-1206(10)60603-5
Descripción
Sumario:BACKGROUND: Upper respiratory tract infection symptoms are a common cause of morbidity. Herbal preparations of the plant Echinacea purpurea have immune-enhancing properties. OBJECTIVE: To compare the frequency of upper respiratory tract symptoms in individuals receiving E purpurea capsules and those receiving placebo to evaluate the preventive efficacy of echinacea. METHODS: In a randomized, double-blind clinical trial, 90 volunteers recruited from hospital personnel were randomly assigned to receive 3 capsules twice daily of either placebo (parsley) or E purpurea for 8 weeks during the winter months. Upper respiratory tract symptoms were reported weekly during this period. RESULTS: Fifty-eight individuals were included in the final data analysis: 28 in the echinacea group and 30 in the placebo group. Individuals in the echinacea group reported 9 sick days per person during the 8-week period, whereas the placebo group reported 14 sick days (z = −0.42; P = .67). Mild adverse effects were noted by 8% of the echinacea group and 7% of the placebo group (P = .24). CONCLUSION: Prophylactic treatment with commercially available E purpurea capsules did not significantly alter the frequency of upper respiratory tract symptoms compared with placebo use.